BioCardia Inc.
BCDA
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.3M
Close$
$0.30
63.2% downside
Current Fair Value
63.2% downsideOvervalued by 63.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.30 Million |
|---|---|
| Enterprise Value | $4.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.23 |
| Beta | 0.44 |
| Outstanding Shares | 10,812,419 |
Return
| Return on Equity | 729.36% |
|---|---|
| Return on Assets | -454.15% |
| Return on Invested Capital | 520.17% |
Valuation & Multiples
| P/E Ratio | -0.89 |
|---|---|
| PEG | 5.32 |
| Price to Sales | - |
| Price to Book Ratio | -0.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.86 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -0.39 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.35%▼ 3.39% |
|---|---|
| Total Invested | $831,135▲ 2.32% |
| Investors Holding | 18▼ 2.00% |
ESG Score
No data
About BioCardia Inc.
27 employees
CEO: Peter Altman BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are ...